The role of TRAP1, the mitochondrial Hsp90 in cancer progression and as a possible therapeutic target

被引:1
|
作者
Sarkar, Sena [1 ]
Halder, Babli [1 ]
机构
[1] Gurudas Coll, Dept Zool, 1-1 Suren Sarkar Rd, Kolkata 700054, India
来源
CURRENT SCIENCE | 2023年 / 124卷 / 06期
关键词
Apoptosis; cancer progression; drug resistance; heat shock proteins; tumour cells; RECEPTOR-ASSOCIATED PROTEIN-1; PERMEABILITY TRANSITION; CELL-CYCLE; CHAPERONE TRAP1; ENDOPLASMIC-RETICULUM; MATRIX METALLOPROTEINASES; CLINICAL-SIGNIFICANCE; MOLECULAR CHAPERONES; OXIDATIVE-METABOLISM; PROTECTS CELLS;
D O I
10.18520/cs/v124/i6/671-685
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hsp90, a 90 kDa heat shock protein (HSP), is a molecular chaperone involved in various cellular processes. It is highly conserved across species and plays a critical role in protein folding quality control, protein degradation and, most importantly, stabilizing proteins against heat stress. Emerging evidences suggest that HSPs accumu-late not only in stressful conditions, but also in patho-physiological conditions and tumours. They play a role in refolding partially damaged functional proteins and also stabilize cell survival factors. Studies also suggest the role of organelle-specific Hsp90 chaperones in these processes, which further adds to the complexity. These findings make the Hsp90 family a potent target for anti-cancer drugs. Tumour necrosis factor receptor -associ-ated protein 1 (TRAP1), the mitochondrial homolog of Hsp90, is found to play a pivotal role in mitochondrial bioenergetics, maintenance of mitochondrial integrity and mounting stress responses. Tumour cells exhibit a peculiar phenotype known as the Warburg effect, where they evade the mitochondrial oxidative phosphorylation and produce ATP by aerobic glycolysis. Studies suggest TRAP1 as a key regulator in this metabolic switchover along with a pivotal role in drug resistance and anti-apoptotic effects. This article discusses the molecular mechanisms of TRAP1 to regulate cancer growth, its role in protecting cells from apoptosis and toxicity from anti-cancer drugs. The possibility of TRAP1 as a poten-tial target for cancer therapies in the near future based on new-age therapeutic strategies by inhibiting the pro-tein is also discussed here.
引用
收藏
页码:671 / 685
页数:15
相关论文
共 50 条
  • [1] The ATPase cycle of the mitochondrial Hsp90 analog trap1
    Leskovar, Adriane
    Wegele, Harald
    Werbeck, Nicolas D.
    Buchner, Johannes
    Reinstein, Jochen
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (17) : 11677 - 11688
  • [2] The Mitochondrial Hsp90 TRAP1 and Alzheimer's Disease
    Dekker, Francoise A.
    Rudiger, Stefan G. D.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [3] The Role of HSP90 and TRAP1 Targets on Treatment in Hepatocellular Carcinoma
    Kumar, P. K. Praveen
    Sundar, Harini
    Balakrishnan, Kamalavarshini
    Subramaniam, Sakthivel
    Ramachandran, Hemalatha
    Kevin, M.
    Gromiha, M. Michael
    MOLECULAR BIOTECHNOLOGY, 2024, : 1367 - 1381
  • [4] The Mitochondrial HSP90 Paralog TRAP1: Structural Dynamics, Interactome, Role in Metabolic Regulation, and Inhibitors
    Joshi, Abhinav
    Ito, Takeshi
    Picard, Didier
    Neckers, Len
    BIOMOLECULES, 2022, 12 (07)
  • [5] Cytosolic Hsp90α and its mitochondrial isoform Trap1 are differentially required in a breast cancer model
    Vartholomaiou, Evangelia
    Madon-Simon, Marta
    Hagmann, Stephane
    Muehlebach, Guillaume
    Wurst, Wolfgang
    Floss, Thomas
    Picard, Didier
    ONCOTARGET, 2017, 8 (11) : 17428 - 17442
  • [6] TRAP-1, the mitochondrial Hsp90
    Altieri, Dario C.
    Stein, Gary S.
    Lian, Jane B.
    Languino, Lucia R.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2012, 1823 (03): : 767 - 773
  • [7] The Structural Asymmetry of Mitochondrial Hsp90 (Trap1) Determines Fine Tuning of Functional Dynamics
    Moroni, Elisabetta
    Agard, David A.
    Colombo, Giorgio
    JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2018, 14 (02) : 1033 - 1044
  • [8] The Therapeutic Target Hsp90 and Cancer Hallmarks
    Miyata, Yoshihiko
    Nakamoto, Hitoshi
    Neckers, Len
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (03) : 347 - 365
  • [9] Hsp90 as a therapeutic target in prostate cancer
    Solit, DB
    Scher, HI
    Rosen, N
    SEMINARS IN ONCOLOGY, 2003, 30 (05) : 709 - 716
  • [10] HSP90 as a therapeutic target in colorectal cancer
    Nagaraju, Ganji Purnachandra
    Willingham, Field F.
    Woods, Kevin E.
    Sullivan, Patrick
    Landry, Jerome C.
    Diaz, Roberto
    El-Rayes, Bassel F.
    CANCER RESEARCH, 2014, 74 (19)